Celldex Therapeutics Inc. (NASDAQ:CLDX) shares saw strong trading volume on Friday . 3,772,675 shares were traded during trading, an increase of 115% from the previous session’s volume of 1,751,799 shares.The stock last traded at $3.88 and had previously closed at $4.16.

Several equities analysts have commented on the stock. Jefferies Group reissued a “hold” rating and set a $4.00 target price on shares of Celldex Therapeutics in a research report on Friday, May 6th. Wedbush reissued a “neutral” rating and set a $3.00 target price on shares of Celldex Therapeutics in a research report on Friday, May 6th. Finally, Cowen and Company reissued an “outperform” rating and set a $12.00 target price on shares of Celldex Therapeutics in a research report on Tuesday, June 7th. Six equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $10.75.

The firm’s market cap is $397.15 million. The stock’s 50 day moving average is $4.56 and its 200 day moving average is $4.72.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.02. During the same period in the prior year, the firm posted ($0.33) earnings per share. The company earned $1.39 million during the quarter, compared to the consensus estimate of $0.96 million. The company’s revenue was down 36.4% compared to the same quarter last year. On average, analysts predict that Celldex Therapeutics Inc. will post ($1.34) EPS for the current year.

Celldex Therapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.